Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.
1. A method for determining response to treatment with olanzapine for a human subject having or suspected of having schizophrenia comprising:
determining the SULT4A1-1 haplotype in a sample, wherein the SULT4A1-1 haplotype is defined as a haplotype comprising a C allele at rs763120, a combination of an A allele at rs2285162 and a G allele at rs2285167, or the combination of a T allele at rs2285166 and G allele at rs2285167, and
determining a response to treatment wherein if the human subject comprises the SULT4A1-1 haplotype the subject is more likely to exhibit a favorable response to olanzapine and if the subject does not comprise the SULT4A1-1 haplotype the subject is less likely to exhibit a favorable response to olanzapine.
2. A method for selecting a pharmacotherapeutic treatment plan for a human subject having or suspected of having schizophrenia comprising:
determining the SULT4A1-1 haplotype in a sample, wherein the SULT4A1-1 haplotype is defined as a haplotype comprising a C allele at rs763120, a combination of an A allele at rs2285162 and a G allele at rs2285167, or the combination of a T allele at rs2285166 and G allele at rs2285167 and wherein if the subject comprises SULT4A1-1 haplotype the subject is more likely to exhibit a favorable response to olanzapine and if the subject does not comprise a SULT4A1-1 haplotype the subject is less likely to exhibit a favorable response to olanzapine,
selecting a pharmacotherapeutic treatment plan based on the SULT4A1-1 haplotype, and
treating the subject with the selected pharmacotherapeutic treatment.
3. The method of claim 2 , wherein if the subject comprises a SULT4A1-1 haplotype, then the method further comprises treating the subject with olanzapine.
4. The method of claim 2 , wherein if the subject does not comprise the SULT4A1-1 haplotype, then the method further comprises treating the subject with an anti-psychotic treatment other than olanzapine.
5. The method of claim 4 , wherein the anti-psychotic treatment other than olanzapine comprises treating the subject with risperidone, quetiapine, or perphenzazine.
6. The method of claim 2 , further defined as a method for treating a subject having schizophrenia and determined to have a SULT4A1-1 haplotype, comprising treating the subject with olanzapine.
7. The method of claim 3 further defined as a method for treating a subject having schizophrenia and determined not to have a SULT4A1-1 haplotype, comprising treating the subject with a non-olanzapine anti-psychotic treatment.